ABBV · News · 20260930N
Revenue Performance and Mix
AbbVie Inc. · 2026-09-30 · Importance 38 · Surprise 40 · No source text
AbbVie’s second-quarter revenue increased 10% year over year, according to third-party analyst reporting. Skyrizi and Rinvoq were identified as the primary growth drivers. The reported mix shift reflects continued expansion of AbbVie’s newer immunology products following Humira’s patent-related decline.
Key facts
- AbbVie's Q2 revenue increased by 10%, driven by Skyrizi and Rinvoq. source
- AbbVie shares experienced a 1.1% decline and were trading 19.0% above GuruFocus' intrinsic value estimate. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +9.1% | AbbVie's Q2 revenue increased by 10%, driven by Skyrizi and Rinvoq. |